BRITISH JOURNAL

OF

HAEMATOLOGY

EDITORS: IAN HANN, FINBARR COTTER, JOHN REILLY

ASSOCIATE EDITORS

H. E. Broxmeyer, A. K. Burnett, M. Greaves, M. Y. Gordon,
I. R. Peake, M. J. Pippard, I. A. G. Roberts, N. Russell, S. L. Thein, L. Williamson

EDITORIAL BOARD

I. R. Peake *Chairman*
R. Auer, T. Baglin, B. J. Bain, M. Barnett, B. Bennett, J. Boultwood, C. Camaschella,
R. Chopra, C. J. Eaves, C. Fegan, P. Fenaux, A. Goodeve, A. R. Green, J. D. Griffin,
H. Heslop, T. L. Holyoake, M. Le Beau, D. Linch, M. Makris, C. Mecucci, D. R. Miller,
P. A. H. Moss, A. Nurden, D. Provan, D. Pamphilon, D. Rees, D. Rund, O. P. Smith,
M. Worwood

Volume 123
Pages 1–968

Blackwell
Publishing

2003

© 2003 *British Journal of Haematology* Blackwell Publishing Ltd
Published by Blackwell Publishing Ltd
Editorial Offices:
Blackwell Publishing Ltd, 101 George Street, Edinburgh EH2 3ES, UK
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK
Blackwell Publishing Asia Pty, 550 Swanston Street, Carlton South, Melbourne, VIC 3053, Australia, and TK Building, 2-38-14 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Blackwell Publishing Europe Ltd, 10 rue Casimir Delavigne, F-75006 Paris, France
Blackwell Verlag GmgH, Kurfürstendamm 57, D-10707 Berlin, Germany
Blackwell Publishing KK, NK Building 3F, 2–8–12 Iwamotocho, Chiyodaku, Tokyo 101-0032, Japan
Blackwell Publishing Inc, Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA
Blackwell Munksgaard, 1, Rosenørns Allè, P.O. Box 227, DK-1502 Copenhagen V, Denmark

Authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users of the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the CCC. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

British Journal of Haematology is covered by *ADONIS, ASCA, Chemical Abstracts, Current Awareness in Biological Sciences, Current Contents, Current Clinical Cancer, Index Medicus, ISI/BIOMED,* and *Science Citation Index.*

ISSN 0007-1048

Typeset by Scientific Publishing Services, India, and printed by the Alden Group, Oxford.

BRITISH JOURNAL OF HAEMATOLOGY

Volume 123, Issue 1, October-I 2003

IMAGES IN HAEMATOLOGY

1 **Pulmonary veno-occlusive disease following allogeneic peripheral blood stem cell transplantation for chronic myeloid leukaemia**
M. Mukai, M. Kondo, T. Bohgaki, A. Notoya and M. Kohno

2 **Circulating neuroblastoma cells in peripheral blood**
V. Moodley and R. Pool

HISTORICAL REVIEWS

3 **William Osler's legacy and his contribution to haematology**
M. J. Stone

19 **Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells**
E. Crivellato, C. A. Beltrami, F. Mallardi and D. Ribatti

GUIDELINE

22 **Guidelines on the use of colony-stimulating factors in haematological malignancies**
A. Pagliuca, P. A. Carrington, R. Pettengell, S. Rule and J. Keidan on behalf of the Haemato-Oncology Task Force of the British Committee for Standards in Haematology

HAEMATOLOGICAL MALIGNANCY

34 **Bcr-Abl upregulates cytosolic p21$^{WAF-1/CIP-1}$ by a phosphoinositide-3-kinase (PI3K)-independent pathway**
K. Keeshan, T. G. Cotter and S. L. McKenna

45 **Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia**
G. Mathonnet, M. Krajinovic, D. Labuda and D. Sinnett

49 **Prognostic significance of quantitative analysis of *WT1* gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia**
M. Garg, H. Moore, K. Tobal and J. A. L. Yin

60 **Geographical and ecological analyses of childhood acute leukaemias and lymphomas in north-west England**
R. J. Q. McNally, R. D. Alston, D. P. Cairns, O. B. Eden and J. M. Birch

66 **The P2X7 receptor gene polymorphism 1513 A → C has no effect on clinical prognostic markers, *in vitro* sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia**
J. Starczynski, C. Pepper, G. Pratt, L. Hooper, A. Thomas, T. Hoy, D. Milligan, P. Bentley and C. Fegan

72 **Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival**
T. Nakamaki, Y. Hamano, J.-I. Hisatake, A. Yokoyama, K.-I. Kawakami, S. Tomoyasu, Y. Honma and P. Koeffler

81 **The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups**
M. Oosterveld, S. H. Wittebol, W. A. J. G. Lemmens, B. A. L. M. Kiemeney, A. Çatik, P. Muus, A. V. M. B. Schattenberg and T. J. M. de Witte

90 **Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma**
S. Guyomard, G. Salles, M. Coudurier, H. Rousset, B. Coiffier, J. Bienvenu and N. Fabien

Short reports

100 **Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia**
S. Stoneham, L. Lennard, P. Coen, J. Lilleyman and V. Saha

103 **Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion**
F. Baron, P. Frère, G. Fillet and Y. Beguin

106 **Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma**
E. Terpos, M. Politou, R. Szydlo, J. M. Goldman, J. F. Apperley and A. Rahemtulla

TRANSPLANTATION

110 **Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity**
R. Chohan, R. Vij, D. Adkins, W. Blum, R. Brown, M. Tomasson, S. Devine, T. Graubert, L. T. Goodnough, J. F. DiPersio and H. Khoury

114 **The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation**
J. P. Kerr, E. Liakopolou, J. Brown, J. M. Cornish, D. Fleming, E. Massey, A. Oakhill, D. H. Pamphilon, S. P. Robinson, A. Totem, A. M. P. I. Valencia and D. I. Marks

119 **Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation**
D. Nachbaur, B. Kircher, K. Eisendle, K. Lätzer, M. Haun and G. Gastl

PLATELETS, HAEMOSTASIS AND THROMBOSIS

127 **Bernard–Soulier syndrome due to the homozygous Asn-45Ser mutation in GPIX: an unexpected, frequent finding in Germany**
U. J. H. Sachs, H. Kroll, A. C. Matzdorff, H. Berghöfer, J. A. Lõpez and S. Santoso

132 **Molecular, ultrastructural and functional characterization of a Spanish family with Hermansky–Pudlak syndrome: role of insC974 in platelet function and clinical relevance**
R. González-Conejero, J. Rivera, G. Escolar, I. Zuazu-Jausoro, V. Vicente and J. Corral

Short reports

139 **Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis**
J. O'Donnell, R. A. Manning and M. A. Laffan

142 **Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy**
M. Michel, M. V. Novoa and J. B. Bussel

RED CELLS AND IRON

147 **Pure red cell aplasia associated with expansion of $CD3^+$ $CD8^+$ granular lymphocytes expressing cytotoxicity against HLA-E^+ cells**
K. L. Mori, H. Furukawa, K. Hayashi, K.-J. J. Sugimoto and K. Oshimi
154 **A novel deletion causing $(\epsilon\gamma\delta\beta)^\circ$ thalassaemia in a Chilean family**
L. Game, J. Bergounioux, J. P. Close, B. E. Marzouka and S. L. Thein
160 **Quiescent $CD34^+$ early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines; role of FLIP**
J. Ratajczak, M. Kucia, R. Reca, J. Zhang, B. Machalinski and M. Z. Ratajczak
Short reports 170 **Hypoxic response of iron absorption is not affected by the *Hfe* gene knock-out in mice**
A. H. Laftah, R. J. Simpson, N. Beaumont, S. Bahram, K. Schümann and S. K. S. Srai
173 **Cytogenetic abnormalities in paroxysmal nocturnal haemoglobinuria usually occur in haematopoietic cells that are glycosylphosphatidylinositol-anchored protein (GPI-AP) positive**
E. M. Sloand, M. Fuhrer, K. Keyvanfar, L. Mainwaring, J. Maciejewski, Y. Wang, S. Johnson, A. J. Barrett and N. S. Young

HAEMOPOIESIS AND LEUCOCYTES

177 **The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region**
N. Sezaki, F. Ishimaru, T. Tabayashi, I. Kataoka, K. Nakase, K. Fujii, T. Kozuka, H. Nakayama, M. Harada and M. Tanimoto

CORRESPONDENCE

184 **Paediatric myelodysplasia**
M. M. Reid
185 **Paediatric myelodysplasia – response to M. M. Reid**
S. J. Passmore, C. A. Stiller, H. Kempski and I. M. Hann

186 **ERRATA**
187 **BOOK REVIEWS**
190 **ANNOUNCEMENT**

Volume 123, Issue 2, October-II 2003

IMAGES IN HAEMATOLOGY

191 **Malignant sarcoma masquerading as a pseudotumour in a patient with mild haemophilia**
P. Connor, B. Cheung and S. Rangarajan
192 **Atypical large granular lymphocytes in a child**
F. Girodon, L. Faivre, N. Devillier, P. M. Carli and M. Maynadié

REVIEW

193 **The role of haploidentical stem cell transplantation in the management of children with haematological disorders**
P. Veys, P. Amrolia and K. Rao

HISTORICAL REVIEW

207 **Haematology at the Hammersmith hospital and Royal Postgraduate Medical School 1934–1994**
A. V. Hoffbrand

HAEMATOLOGICAL MALIGNANCY

219 **Cytogenetic findings in adult *de novo* acute myeloid leukaemia. A population-based study of 303/337 patients**
B. S. Preiss, G. B. Kerndrup, K. G. Schmidt, A. G. Sørensen, N.-A. T. Clausen, O. V. Gadeberg, T. Mourits-Andersen and N. T. Pedersen on behalf of the AML study Group Region of Southern Denmark

235 **Possible regulation of Wilms' tumour gene 1 (*WT1*) expression by the paired box genes *PAX2* and *PAX8* and by the haematopoietic transcription factor *GATA-1* in human acute myeloid leukaemias**
J. M. Siehl, E. Thiel, K. Heufelder, E. Snarski, S. Schwartz, V. Mailänder and U. Keilholz

243 **Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia**
E. Coustan-Smith, R. C. Ribeiro, J. E. Rubnitz, B. I. Razzouk, C.-H. Pui, S. Pounds, M. Andreansky, F. G. Behm, S. C. Raimondi, S. A. Shurtleff, J. R. Downing and D. Campana

253 **Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities**
T. Rasmussen, K. Theilgaard-Mönch, H. R. Hudlebusch, M. Lodahl, H. E. Johnsen and I. M. S. Dahl

263 **Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications**
Y. Saeki, T. Mima, T. Ishii, A. Ogata, H. Kobayashi, S. Ohshima, T. Ishida, Y. Tabunoki, H. Kitayama, M. Mizuki, Y. Katada, H. Asaoku, M. Kitano, N. Nishimoto, K. Yoshizaki, M. Maeda, S. Kon, N. Kinoshita, T. Uede and I. Kawase

271 **Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma**
G. Martinelli, D. Laszlo, F. Bertolini, R. Pastano, P. Mancuso, A. Calleri, A. Vanazzi, P. Santoro, F. Cavalli and E. Zucca

278 **Successful treatment of refractory pure red cell aplasia associated with lympho-proliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H)**
X. Ru and H. A. Liebman

282 **Predictive value of early ^{18}F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma**
B. Schot, G. van Imhoff, J. Pruim, W. Sluiter, W. Vaalburg and E. Vellenga

288 **DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome**
M. Ueda, J. Ota, Y. Yamashita, Y. L. Choi, R. Ohki, T. Wada, K. Koinuma, Y. Kano, K. Ozawa and H. Mano

297 **Granulomatous slack skin disease – disease features and response to pentostatin**
N. Osuji, L. Fearfield, E. Matutes, A. C. Wotherspoon, C. Bunker and D. Catovsky

Short report 305 **Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma**
M. A. Thompson, T. E. Witzig, S. Kumar, M. M. Timm, J. Haug, R. Fonseca, P. R. Greipp, J. A. Lust and S. V. Rajkumar

TRANSPLANTATION

309 **T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions**
S. D'Sa, K. Peggs, A. Pizzey, S. Verfuerth, D. Thuraisundaram, M. Watts, H. White, G. Hale, H. Waldmann, A. Goldstone, S. Mackinnon and K. Yong

Short report 323 **T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation**
E. J. Lowe, V. Turner, R. Handgretinger, E. M. Horwitz, E. Benaim, G. A. Hale, P. Woodard and W. Leung

PLATELETS, HAEMOSTASIS AND THROMBOSIS

327 **Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone**
M.-M. Samama, R. A. Rached, M.-H. Horellou, S. Aquilanti, V. G. Mathieux, G. Plu-Bureau, I. Elalamy and J. Conard

335 **A multicentre assessment of the endogenous thrombin potential using a continuous monitoring amidolytic technique**
A. S. Lawrie, E. Gray, D. Leeming, S. J. Davidson, G. Purdy, R. Iampietro, S. Craig, P. Rigsby and I. J. Mackie

Short report 342 **Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy**
Y. Dargaud, M. C. Trzeciak, S. Meunier, C. Angei, D. Pellechia, C. Négrier and C. Vinciguerra

RED CELLS AND IRON

346 **Familial polycythemia vera with Budd–Chiari syndrome in childhood**
H. Cario, H. L. Pahl, K. Schwarz, C. Galm, M. Hoffmann, M. Burdelski, E. Kohne and K.-M. Debatin

353 **Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of β-thalassaemia trait**
C. Garner, T. K. Dew, R. Sherwood, D. Rees and S. L. Thein

359 **Causes of death in sickle cell disease: an autopsy study**
E. A. Manci, D. E. Culberson, Y.-M. Yang, T. M. Gardner, R. Powell, J. Haynes Jr, A. K. Shah and V. N. Mankad and Investigators of the Cooperative Study of Sickle Cell Disease

CORRESPONDENCE

366 **Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate**
R. A. Mesa, D. P. Steensma, J. Hoyer and R. P. Ketterling
367 **Severe acute respiratory syndrome and lupus anticoagulants in children**
E. Y. Chow and W. K. Chiu
368 **Malignancies in sickle cell disease patients treated with hydroxyurea**
A. Ferster, E. Sariban and N. Meuleman for the Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea
369 **Lithium effects on neutrophil motility in Shwachman–Diamond syndrome: evaluation by computer-assisted image analysis**
A. Azzarà, G. Carulli and M. Petrini
370 **Prognostic features of splenic lymphoma with villous lymphocytes**
E. Iannitto, E. Ammatuna, A. M. Florena and V. Franco
371 **Erythrocytosis and the Chuvash von Hippel-Lindau mutation**
M. J. Percy, M. E. J. Beard, C. Carter and S. L. Thein
372 **Endothelial cells express normal cellular prion protein**
R. Starke, P. Harrison, R. Gale, I. Mackie, O. Drummond, I. MacGregor and S. Machin
373 **Heparin-induced thrombocytopenia: pathogenesis and management**
R. A. Saad
374 **Heparin-induced thrombocytopenia: pathogenesis and management – Response to Rasheed Saad**
T. E. Warkentin

Volume 123, Issue 3, November-I 2003

IMAGES IN HAEMATOLOGY

377 **Splenunculectomy in autoimmune thrombocytopenic purpura**
P. A. Fields, H. Cohen and K. G. Patterson
378 **Splenosis peritonei**
S. Luminari, M. De Santis, A. Casolo and M. Federico
379 **The reticulin stain in bone marrow biopsies – beyond marrow fibrosis**
J. Ahluwalia, G. Garewal, R. Das and K. Vaiphei

REVIEW

380 **Role of the microenvironment in chronic lymphocytic leukaemia**
F. Caligaris-Cappio

HISTORICAL REVIEW

389 **Louis Diamond and his contribution to haematology**
W. C. Mentzer

HAEMATOLOGICAL MALIGNANCY

396 **Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia**
J. M. Chessells, P. Veys, H. Kempski, P. Henley, A. Leiper, D. Webb and I. M. Hann

406 **Adult T-cell leukaemia/lymphoma-like human T-cell leukaemia virus-1 replication in infective dermatitis**
A.-S. Gabet, M. Kazanji, P. Couppie, E. Clity, J.-F. Pouliquen, D. Sainte-Marie, C. Aznar and E. Wattel

413 **Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia**
J. Tiesmeier, A. Czwalinna, C. Müller-Tidow, J. Krauter, H. Serve, G. Heil, A. Ganser and W. Verbeek

420 **Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias**
P. Virgo, P. A. Denning-Kendall, C. L. Erickson-Miller, S. Singha, R. Evely, J. M. Hows and S. D. Freeman

431 **Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia**
D. L. Johnston, S. Meshinchi, K. E. Opheim, M. G. Pallavicini, J. Feusner, W. G. Woods, B. J. Lange, J. P. Radich and I. D. Bernstein

436 **Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia**
D. A. Thomas, E. Estey, F. J. Giles, S. Faderl, J. Cortes, M. Keating, S. O'Brien, M. Albitar and H. Kantarjian

442 **Double Philadelphia masquerading as chromosome 20q deletion – a new recurrent abnormality in chronic myeloid leukaemia blast crisis**
A. G. Reid, S. Swanton, C. Grace, L. J. Campbell, A. R. Green and E. P. Nacheva Together with the United Kingdom Cancer Cytogenetics Group (UKCCG)

449 **HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders**
M. Battiwalla, J. Melenhorst, Y. Sauntharajah, R. Nakamura, J. Molldrem, N. S. Young and A. J. Barrett

454 **^{18}FDG positron emission tomography versus ^{67}Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma**
J. M. Zijlstra, O. S. Hoekstra, P. G. H. M. Raijmakers, E. F. I. Comans, J. J. M. van der Hoeven, G. J. J. Teule, A. R. Jonkhoff, H. v Tinteren, A. A. Lammertsma and P. C. Huijgens

463 **The clinical impact of expert pathological review on lymphoma management: a regional experience**
J. F. Lester, S. D. Dojcinov, R. L. Attanoos, C. J. O'Brien, T. S. Maughan, E. T. Toy and C. H. Poynton

Short reports

469 **Bi-allelic silencing of the Fanconi anaemia gene *FANCF* in acute myeloid leukaemia**
M. Tischkowitz, N. Ameziane, Q. Waisfisz, J. P. De Winter, R. Harris, T. Taniguchi, A. D'Andrea, S. V. Hodgson, C. G. Mathew and H. Joenje

472 **The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders**
O. Bock, E. Serinsöz, M. Neusch, J. Schlué and H. Kreipe

475 **Frequent aberrant promoter hypermethylation of O^6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas**
D. Rossi, G. Gaidano, A. Gloghini, C. Deambrogi, S. Franceschetti, E. Berra, M. Cerri, C. Vendramin, A. Conconi, A. Viglio, G. Muti, P. Oreste, E. Morra, M. Paulli, D. Capello and A. Carbone

TRANSPLANTATION

479 **Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission**
M. W. Drummond, D. Marin, R. E. Clark, J. L. Byrne, T. L. Holyoake and A. Lennard on behalf of the United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party

484 **Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience**
A. B.-T. Fassas, B. Barlogie, S. Ward, S. Jagannath, D. Vesole, S. Mattox, D. Siegel, F. Muwalla, M. Zangari, E. Anaissie, F. V. Rhee, R. Thertulien, C.-K. Lee, R. Desikan, V. Arzumanian, J. Mccoy and G. Tricot

PLATELETS, HAEMOSTASIS AND THROMBOSIS

490 **Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?**
K. Hsieh, P. Knöbl, C. Rintelen, P. A. Kyrle, P. Quehenberger, C. Bialonczyk, H. Partsch, K. Lechner and I. Pabinger

496 **Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C**
A. D. Mumford, J. H. McVey, C. V. Morse, K. Gomez, M. Steen, E. A. Norstrom, E. G. D. Tuddenham, B. Dahlback and P. H. B. Bolton-Maggs

502 **Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study**
E. Santagostino, A. Gringeri, L. Berardinelli, C. Beretta, M. Muça-Perja and P. M. Mannucci

507 **Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound**
C. J. van Rooden, F. R. Rosendaal, R. M. Y. Barge, J. A. van Oostayen, F. J. M. van der Meer, A. Edo Meinders and M. V. Huisman

513 **Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia**
P. Johansson, A. Ricksten, L. Wennström, L. Palmqvist, J. Kutti and B. Andréasson

517 **Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution**
V. De Sanctis, M. G. Mazzucconi, A. Spadea, M. Alfò, M. Mancini, L. Bizzoni, M. Peraino and F. Mandelli

522 **Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP): a prospective analysis**
T. Romani de Wit, R. Fijnheer, H.-J. Brinkman, S. Kersting, R. J. Hene and J. A. van Mourik

HAEMOPOIESIS AND LEUCOCYTES

528 **Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth**
K. Kato, K. Kamezaki, K. Shimoda, A. Numata, T. Haro, K. Aoki, F. Ishikawa, K. Takase, H. Ariyama, T. Matsuda, T. Miyamoto, K. Nagafuji, H. Gondo, K.-I. Nakayama and M. Harada

Short reports

536 **Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms**
A. Rutgers, P. Heeringa, J. E. H. M. Giesen, R. T. Theunissen, H. Jacobs and J. W. C. Tervaert

539 **Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow**
M. Marusic-Vrsalovic, M. Dominis, B. Jaksic and R. Kusec

542 **Lamin B-receptor mutations in Pelger–Huët anomaly**
S. Best, F. Salvati, J. Kallo, C. Garner, S. Height, S. L. Thein and D. C. Rees

RED CELLS AND IRON

545 **Differential apoptosis and Fas expression on GPI-negative and GPI-positive stem cells: a mechanism for the evolution of paroxysmal nocturnal haemoglobinuria**
M. M. Ismail, J. A. Tooze, J. A. Flynn, E. C. Gordon-Smith, F. M. Gibson, T. R. Rutherford and M. O. Elebute

552 **Evaluation of the haemopoietic reservoir in *de novo* haemolytic paroxysmal nocturnal haemoglobinuria**
M. O. Elebute, S. Rizzo, J. A. Tooze, J. C. W. Marsh, E. C. Gordon-Smith and F. M. Gibson

CORRESPONDENCE

561 **Spectrum of T-large granular lymphocyte lymphoproliferations: ranging from expanded activated effector T cells to T-cell leukaemia**
A. W. Langerak, Y. Sandberg and J. J. M. van Dongen

562 **Bone marrow biopsy related haemorrhage and low molecular weight heparin**
N. J. Morley and M. Makris

563 **ERRATA**

Volume 123, Issue 4, November-II 2003

IMAGES IN HAEMATOLOGY

565 **Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab**
V. Pitini, C. Arrigo and G. Barresi

566 **2-[18] Fluoro-2-deoxy-D-glucose positron emission tomography imaging in non-secretory multiple myeloma**
I. Gavish, M. Bennett, O. Israel and R. Bar-Shalom

567 **Lymphomatous category of immunoproliferative small intestinal disease**
A. Androulaki, A. C. Lazaris and K. Papadimitriou

REVIEWS

568 **Zebrafish as a model organism for blood diseases**
J. Berman, K. Hsu and A. T. Look
577 **Apoptosis and leukaemia**
H. J. M. Brady

ANNOTATION

586 **Medical nemesis and childhood ITP**
J. Lilleyman

HAEMATOLOGICAL MALIGNANCY

590 **Mutual exclusion of t(11;18)(q21;q21) and numerical chromosomal aberrations in the development of different types of primary gastric lymphomas**
M. I. Schreuder, M. A. Hoeve, K. M. Hebeda, M. A. Verdijk, M. J. Ligtenberg, F. J. Bot, A. Chott and J. H. J. M. van Krieken
600 **Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b**
M. Noguchi, K. Mori, S. Yamazaki, K. Suda, N. Sato and K. Oshimi
606 **HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features**
H. Suefuji, K. Ohshima, N. Hayabuchi, K. Nakamura and M. Kikuchi
613 **TCR Vβ repertoire analysis in $CD56^{+}$ $CD16^{dim/-}$ T-cell large granular lymphocyte leukaemia: association with CD4 single and CD4/CD8 double positive phenotypes**
M. Karasawa, T. Mitsui, A. Isoda, Y. Tsumita, H. Irisawa, A. Yokohama, H. Handa, T. Matsushima, N. Tsukamoto, H. Murakami and Y. Nojima
621 **Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma**
N. Niitsu, H. Nakamine, M. Okamoto, H. Akamatsu, Y. Honma, M. Higashihara, J. Okabe-Kado and M. Hirano
631 **Smoldering multiple myeloma: natural history and recognition of an evolving type**
L. Rosiñol, J. Bladé, J. Esteve, M. Aymerich, M. Rozman, S. Montoto, E. Giné, E. Nadal, X. Filella, R. Queralt, A. Carrió and E. Montserrat
637 **Alterations of *RAS* signalling in Chinese multiple myeloma patients: absent *BRAF* and rare *RAS* mutations, but frequent inactivation of *RASSF1A* by transcriptional silencing or expression of a non-functional variant transcript**
M. H. L. Ng, K. M. Lau, W. S. Wong, K. W. To, S. H. Cheng, K. S. Tsang, N. P. H. Chan, B. C. S. Kho, K. W. Lo, J. H. M. Tong, C. W. Lam and J. C. W. Chan
646 **Dissociation of putative graft-*versus*-haematopoiesis and graft-*versus*-myeloma effects in patients with rapidly progressive multiple myeloma**
T. Luft, M. Moos, H. Goldschmidt, A. D. Ho and M. Görner
654 **Epigenetic alteration of the *SOCS1* gene in chronic myeloid leukaemia**
T.-C. Liu, S.-F. Lin, J.-G. Chang, M.-Y. Yang, S.-Y. Hung and C.-S. Chang

TRANSPLANTATION

662 **Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation**
C. Junghanss, R. Storb, M. B. Maris, R. A. Carter, B. M. Sandmaier, D. G. Maloney, P. A. McSweeney, L. Corey and M. Boeckh

671 **Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-*versus*-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling**
Y. Akatsuka, E. H. Warren, T. A. Gooley, A. G. Brickner, M.-T. Lin, J. A. Hansen, P. J. Martin, D. K. Madtes, V. H. Engelhard, T. Takahashi and S. R. Riddell

PLATELETS, HAEMOSTASIS AND THROMBOSIS

676 **Oral anticoagulation in surgical procedures: risks and recommendations**
M. Torn and F. R. Rosendaal

683 **New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model**
K. Skomorovski, H. Harpak, A. Ianovski, M. Vardi, T. P. Visser, S. C. C. Hartong, H. H. D. M. van Vliet, G. Wagemaker and Z. Agur

Short report 692 **Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model**
S. Schatz, P. L. Turecek, C. Fiedler, K. Zimmermann, H. Gritsch, J. Voorberg, H. P. Schwarz, F. Dorner and F. Scheiflinger

HAEMOPOIESIS AND LEUCOCYTES

696 **High prevalences of vitamin B_{12} and folic acid deficiency in elderly subjects in Israel**
E. Figlin, A. Chetrit, A. Shahar, O. Shpilberg, A. Zivelin, N. Rosenberg, F. Brok-Simoni, N. Gadoth, B.-A. Sela and U. Seligsohn

702 **Murine marrow-derived mesenchymal stem cell: isolation, *in vitro* expansion, and characterization**
L. da Silva Meirelles and N. B. Nardi

712 **The impact of retroviral suicide gene transduction procedures on T cells**
W. Qasim, D. King, J. Buddle, S. Verfuerth, C. Kinnon, A. J. Thrasher and H. B. Gaspar

720 **Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34$^-$ human stem cells**
R. M. Lemoli, F. Bertolini, M. T. Petrucci, C. Gregorj, M. R. Ricciardi, M. Fogli, A. Curti, C. Rabascio, S. Pandolfi, S. Ferrari, R. Fo, M. Baccarani and A. Tafuri

RED CELLS AND IRON

730 **Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia**
E. Voskaridou, E. Terpos, G. Spina, J. Palermos, A. Rahemtulla, A. Loutradi and D. Loukopoulos

738 **The effects of vitamin E on platelet activity in β-thalassaemia patients**
S. Unchern, N. Laoharuangpanya, N. Phumala, P. Sipankapracha, P. Pootrakul, S. Fucharoen, W. Wanachivanawin and U. Chantharaksri

CORRESPONDENCE

745 **Inappropriate analysis of reproducibility**
J. Delgado, M. C. Fernandez-Jimenez
745 **Response to Delgado and Fernandez-Jimenez**
B. N. Bekele, F. J. Giles and M. Albitar
746 **Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation**
P. Musto, A. M. Carella Jr, M. M. Greco, A. Falcone, G. Sanpaolo, C. Bodenizza, N. Cascavilla, L. Melillo and A. M. Carella
747 **Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide**
L. Mileshkin, H. M. Prince, J. F. Seymour and J. J. Biagi
748 **Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide – Response to Mileshkin *et al.***
S. Luminari, M. Federico and L. Baldini
748 **Constitutional pericentric inversion of chromosome 9 and bone marrow transplantation**
Y.-K. Keung, M. A. Knovich, D. D. Hurd and M. Pettenati
749 ***c-FMS* mutational analysis in acute myeloid leukaemia**
F. M. Abu-Duhier, A. C. Goodeve, G. A. Wilson, I. R. Peake and J. T. Reilly
750 **Immunoplatelet counting: platelet transfusions**
J. Parker-Williams
751 **Response to Dr J Parker-Williams**
S. Norris, D. Pantelidou, D. Smith and M. Murphy
752 **Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide**
A. Saviola, M. Luppi, L. Potenza, M. Morselli, A. Ferrari, G. Riva and G. Torelli

Volume 123, Issue 5, December-I 2003

IMAGES IN HAEMATOLOGY

755 **Cyclosporin neurotoxicity**
B. Patel and I. Kerridge
756 **History revisited...**
C. Ghevaert, D. Oscier and N. Hopkinson
757 **Bilateral subhyaloid haemorrhage in aplastic anaemia**
W.-M. Chan, D. T. L. Liu, C. C. Y. Tham, R. M. Wu and D. S. C. Lam

REVIEWS

758 **New insights into the pathophysiology and management of bone disease in multiple myeloma**
E. Terpos, M. Politou and A. Rahemtulla
770 **Anti-idiotype vaccines**
H. McCarthy, C. H. Ottensmeier, T. J. Hamblin and F. K. Stevenson

GUIDELINE

782 **Guidelines for the diagnosis and management of acquired aplastic anaemia**
J. C. W. Marsh, S. E. Ball, P. Darbyshire, E. C. Gordon-Smith, A. J. Keidan, A. Martin, S. R. McCann, J. Mercieca, D. Oscier, A.W.W.Roques and J. Yin on behalf of the British Committee for Standards in Haematology (BCSH) General Haematology Task Force

HAEMATOLOGICAL MALIGNANCY

802 ***In vitro* efficacy of L-asparaginase in childhood acute myeloid leukaemia**
S. Okada, T. Hongo, S. Yamada, C. Watanabe, Y. Fujii, T. Ohzeki, Y. Horikoshi, T. Ito, M. Yazaki, Y. Komada and A. Tawa

810 **Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study**
G. Juliusson, M. Höglund, K. Karlsson, C. Löfgren, L. Möllgård, C. Paul, U. Tidefelt and M. Björkholm for the Leukemia Group of Middle Sweden

819 **Core-binding factor-β positive acute myeloid leukaemia cells induce T-cell responses**
G.-A. Banat, K. Ihlow, N. Usluoglu, S. Hoppmann, M. Hoeck and H. Pralle

830 **Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide**
S. H. Oertel, M. Papp-Váry, I. Anagnostopoulos, M. W. Hummel, S. Jonas and H. B. Riess

836 **Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study**
O. Rosen, H. J. Müller, N. Gökbuget, W. Langer, N. Peter, S. Schwartz, D. Hähling, F. Hartmann, T. H. Ittel, R. Mück, F. Rothmann, R. Arnold, J. Boos and D. Hoelzer on behalf of the GMALL Study Group

842 **Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome**
M. T. Rubio, N. Dhedin, C. Boucheix, J. H. Bourhis, O. Reman, J. M. Boiron, J. H. Gallo, V. Lhéritier, X. Thomas, D. Fière and J. P. Vernant for the Leucemie Aigue Lymphoblastique de L' Adulte (LALA) Group

850 **Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease**
F. J. Giles, J. M. Vose, K.-A. Do, M. M. Johnson, T. Manshouri, G. Bociek, P. J. Bierman, S. M. O'Brien, M. J. Keating, H. M. Kantarjian, J. O. Armitage and M. Albitar

858 **Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents**
A. Pandiella, X. Carvajal-Vergara, S. Tabera, G. Mateo, N. Gutiérrez and J. F. San Miguel

869 **Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival**
R. Burger, F. Bakker, A. Guenther, W. Baum, D. Schmidt-Arras, T. Hideshima, Y.-T. Tai, R. Shringarpure, L. Catley, G. Senaldi, M. Gramatzki and K. C. Anderson

TRANSPLANTATION

879 **Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes**
B. Stewart, M. Verdugo, K. A. Guthrie, F. Appelbaum and H. J. Deeg

886 **The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma**
B. E. Shaw, K. Peggs, J. M. Bird, J. Cavenagh, A. Hunter, J. A. Madrigal, N. H. Russell, B. Sirohi, K. Towlson, C. D. Williams, D. I. Marks

PLATELETS, HAEMOSTASIS AND THROMBOSIS

896 **Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation**
J. J. Jimenez, W. Jy, L. M. Mauro, L. L. Horstman, C. Soderland and Y. S. Ahn

Short report 903 **Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing *in vivo* platelet clearance**
N. Wolins, J. Lozier, T. L. Eggerman, E. Jones, E. Aguilar-Córdova and J. G. Vostal

HAEMOPOIESIS AND LEUCOCYTES

906 **The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation**
K. R. Muir, C. E. D. Chilvers, C. Harriss, L. Coulson, M. Grainge, P. Darbyshire, C. Geary, J. Hows, J. Marsh, T. Rutherford, M. Taylor and E. C. Gordon-Smith

915 **Transcobalamin deficiency due to activation of an intra exonic cryptic splice site**
F. Namour, A.-C. Helfer, E. V. Quadros, J.-M. Alberto, H. M. Bibi, L. Orning, D. S. Rosenblatt and G. Jean-Louis

921 **Chemical sensitization and regulation of TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell lines**
J. Kang, R. R. Kisenge, H. Toyoda, S. Tanaka, J. Bu, E. Azuma and Y. Komada

933 **Differential effect of dexamethasone on cell death and STAT5 activation during *in vitro* eosinopoiesis**
F. Debierre-Grockiego, V. Fuentes, L. Prin, F. Gouilleux and V. Gouilleux-Gruart

RED CELLS AND IRON

942 **Determination of the breakpoint and molecular diagnosis of a common α-thalassaemia-1 deletion in the Indian population**
R. V. Shaji, S. E. Eunice, S. Baidya, A. Srivastava and M. Chandy

948 **Assessment of a new immunocytochemical technique in HbF-cell counting by a novel objective evaluation method**
A. Tsantes, G. Androutsos, S. Bonovas, D. Vogiatzi, I. Meletis, E. Stamou, A. Stamoulakatou and G. Paterakis

Short report 952 **Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases**
P. Nielsen, R. Fischer, P. Buggisch and G. Janka-Schaub

CORRESPONDENCE

954 **Human leucocyte antigen and human T-cell lymphotropic virus type 1 associated diseases in Brazil**
D. M. Borducchi, M. Gerbase-DeLima, A. Morgun, N. Shulzhenko, M. S. Pombo-de-Oliveira, J. Kerbauy and J. S. Rodrigues de Oliveira

955 **A case of hypereosinophilic syndrome developing Hodgkin's disease after 4 years**
M. Ayyub, M. Anwar, M. Luqman, W. Ali, M. Bashir and B. J. Bain

956 **Cough mixture abuse as a novel cause of megaloblastic anaemia and peripheral neuropathy**
W. Y. Au, J. Tsang, T. S. Cheng, W. S. Chow, Y. C. Woo, S. K. Ma and S. Tam

958 **Efficacy of a single, weekly dose of recombinant erythropoietin in myeladysplastic syndromes**
V. Garypidou, E. Verrou, S. Vakalopoulou V. Perifanis, K. Tziomalos and I. Venizelos

959 **Acquired activated protein C resistance in myeloma patients with venous thromboembolic events**
S. R. Deitcher, T. Choueiri, G. Srkalovic and M. A. Hussein

961 AUTHOR AND KEYWORD INDEXES FOR VOLUME 123